top of page

Optimal CAB Case Study: Enabling and Ensuring Equitable HIV Treatment for Women



This case study, developed by the Optimal CAB with support from CHAI, outlines the mobilization of community members in response to the WHO-issued advisory on the risks of neural tube defects (NTDs) for women using dolutegravir (DTG) in their HIV treatment, including reflections on the implications for access to optimal HIV treatment, choice, and equity.



Related Posts

See All

Comments


  • LinkedIn
  • Facebook
  • Twitter
  • Instagram
  • YouTube

383 Dorchester Avenue, Suite 400

Boston, MA 02127

The goal of the HIV New Product Introduction Toolkit is to stimulate conversations between government, partners, and communities on new product introduction. Please feel free to share any thoughts, questions, or additional resources for consideration by contacting us via email at HIVToolkit@clintonhealthaccess.org.

 

© 2022  Clinton Health Access Initiative - Global HIV Access Program

bottom of page